Base-case peak WW sales ≈ $0.95–1.0 B, reached ~2033–34 (assuming ~2028–29 approval). Range ~$0.5 B bear → ~$1.65 B bull. The number lives or dies on one thing: proving a real tolerability / persistence (ideally off-treatment durability) edge over two entrenched oral MEK inhibitors.
Treatable pool ~19,300 drug-eligible NF1-PN patients (developed markets) × peak share × blended net price ~$222k / patient-year. Bull adds ~10% pool expansion from improved willingness-to-treat.
Both independent model passes converged on a base case near ~$1B; divergence stayed well under 2×, driven mainly by the assumed eligible-PN fraction and price.
Net price blends US (~$315k) / EU5 (~$154k) / Japan (~$173k) / RoW-dev (~$117k) weighted by treated patients. Default ~$222k reflects a US-heavy revenue mix.
| Region | Treatable patients | Net price / patient-yr |
|---|---|---|
| United States | 8,300 | ~$315k |
| EU5 | 5,900 | ~$154k |
| Japan | 2,200 | ~$173k |
| RoW (developed) | 2,900 | ~$117k |
| Total | 19,300 | ~$222k blended |
Maturity mix ≈ 55% adult / 45% pediatric. Therapy is chronic; persistence and AE-driven discontinuation are key revenue-duration levers. SoC anchors: Koselugo ~$350–450M (2024); Gomekli approved Feb 2025.
| Lever | SoC (MEK) | Parity-plus | Clear winner | Category-redefining |
|---|---|---|---|---|
| Response (≥20% vol) | 60–70% | ≥50% | ≥65–70% + faster | ≥75% w/ deep responses |
| Deep response (≥50%) | uncommon | any rate | ≥15–20% | ≥30% / true CRs |
| Off-drug durability | poor (regrowth) | match | slower regrowth | durable / disease-modifying |
| Rash / acneiform | common | lower grade | <½ incidence | negligible |
| Ocular / retinal | boxed concern | reduced | rare, no eye monitoring | absent |
| Cardiac (↓LVEF) | monitored | reduced | no echos needed | absent |
| AE discontinuation | meaningful % | lower | <½ of SoC | near-zero |
| Pediatric growth safety | open concern | comparable | cleaner signal | proven safe chronic |
| Pain / function PRO | tracks volume | match | earlier / larger | decoupled from volume |
| Dosing | oral QD–BID, DDIs | oral parity | QD, fewer DDIs | QD, no monitoring, peds formulation |
| Criterion type | Commercial lever | Why |
|---|---|---|
| Safety deltas | SHARE | Biggest practical driver — captures the ~25% MEK-intolerant pool without head-to-head efficacy superiority. |
| Efficacy depth (deep response) | PRICE | Superiority justifies premium pricing and favorable formulary tier. |
| Off-treatment durability | CATEGORY | The one axis neither incumbent competes on; expands who gets treated and reframes the disease economics. |
Matching MEK efficacy is table stakes; safety wins share; but durability is the only true white space — both approved MEKs share the regrowth-on-discontinuation weakness. This readout separates a solid ~$1B orphan franchise from a category-redefining one.
| Driver | Swing on peak sales | Note |
|---|---|---|
| True "eligible PN" fraction | ± ~$300M | Most uncertain funnel step; symptomatic/progressing definition varies. |
| Peak treated-share | ± ~$350M | Driven by the tolerability/durability differentiation vs 2 incumbents. |
| US net price / IRA pressure | ± ~$120–190M | US is >50% of revenue; orphan pricing partly shielded but not immune. |
$peaksales two-model orchestration. Both auto-assigned roles (Commercial Forecaster + Clinical Differentiation Strategist) ran on a frontier model after the GPT-5.x endpoints failed on network errors. Live web search was unavailable, so figures are anchored to known NF1 epidemiology and SoC data with assumptions stated explicitly. HLX1502's exact mechanism is not public — it is modeled as an oral, better-tolerated (MEK-sparing) agent with efficacy treated as class-comparable until proven. No trial data for HLX1502 was fabricated. Estimates are planning-grade, not investment advice.